Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays
Authors:
Open Access
- 18 January 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (1) , e14540
Abstract
Finding new peptide biomarkers for stomach cancer in human sera that can be implemented into a clinically practicable prediction method for monitoring of stomach cancer. We studied the serum peptidome from two different biorepositories. We first employed a C8-reverse phase liquid chromatography approach for sample purification, followed by mass-spectrometry analysis. These were applied onto serum samples from cancer-free controls and stomach cancer patients at various clinical stages. We then created a bioinformatics analysis pipeline and identified peptide signature discriminating stomach adenocarcinoma patients from cancer-free controls. Matrix Assisted Laser Desorption/Ionization–Time of Flight (MALDI-TOF) results from 103 samples revealed 9 signature peptides; with prediction accuracy of 89% in the training set and 88% in the validation set. Three of the discriminating peptides discovered were fragments of Apolipoproteins C-I and C-III (apoC-I and C-III); we further quantified their serum levels, as well as CA19-9 and CRP, employing quantitative commercial-clinical assays in 142 samples. ApoC-I and apoC-III quantitative results correlated with the MS results. We then employed apoB-100-normalized apoC-I and apoC-III, CA19-9 and CRP levels to generate rules set for stomach cancer prediction. For training, we used sera from one repository, and for validation, we used sera from the second repository. Prediction accuracies of 88.4% and 74.4% were obtained in the training and validation sets, respectively. Serum levels of apoC-I and apoC-III combined with other clinical parameters can serve as a basis for the formulation of a diagnostic score for stomach cancer patients.Keywords
This publication has 37 references indexed in Scilit:
- Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample BiasClinical Chemistry, 2008
- SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate CancerClinical Chemistry, 2008
- Characterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometryJournal of Chromatography A, 2007
- Data analysis of assorted serum peptidome profilesNature Protocols, 2007
- Direct Tandem Mass Spectrometry Reveals Limitations in Protein Profiling Experiments for Plasma Biomarker DiscoveryJournal of Proteome Research, 2005
- Running before we can walk?Nature, 2004
- Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitationsMolecular & Cellular Proteomics, 2004
- The Human Plasma Proteome: History, Character, and Diagnostic ProspectsMolecular & Cellular Proteomics, 2003
- Microarray data normalization and transformationNature Genetics, 2002
- Association Between Serum Apolipoprotein CII Concentration and Coronary Heart DiseasePreventive Medicine, 2002